Deliver Your News to the World

DSM invests in personalized healthcare company IntegraGen SA


Heerlen, NL, 07-Nov-2006, DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has invested EUR 2 mln in IntegraGen, a French biotechnology company specialized in the development and delivery of genetic tests for rapid diagnosis and better (personalized) treatment of complex diseases.

IntegraGenís proprietary GenomeHIPô technology platform identifies disease genes by allowing the rapid comparison of genomes of family members affected with the same disease. Using this platform IntegraGen has established a pipeline of tests in the areas of Metabolic Syndrome (e.g. MODY (Maturity Onset Diabetes of the Young); Type 2 Diabetes; Obesity) and Neuropsychiatric disorders (e.g. Autism; Bi-Polar Disorder).

IntegraGen focuses on the medical/pharma side of personalized healthcare but recognizes the potential of its know how in personalized nutrition, one of the emerging business areas DSM focuses on to realize its longer-term innovation ambitions as formulated in the corporate strategy program Vision 2010 Ė Building on Strengths.

This joint interest has led to a collaboration program in the area of weight management, which is one of the important focus areas within the field of Personalized Nutrition.

Following DSMís acquisition of Lipid Technologies Provider and the investment in Sciona, this investment is a next stepping stone in weight management and Personalized Nutrition, which moves DSM into an excellent position for future developments in these fields.

DSM Venturing
DSM Venturing is an active investor in start-up companies and Venture Capital Funds in DSMís strategic growth fields Nutrition, Pharma and Performance Materials. DSM Venturingís mission is to explore emerging markets and technologies in these strategic growth fields in order to enhance DSMís product portfolio and create value. DSM Venturing also plays an active role in the development of several new DSM business opportunities in the so-called emerging business areas Biomedical Materials, Industrial (White) Biotechnology, Specialty Packaging and Personalized Nutrition. For more information about DSM Venturing see

IntegraGen is a pioneer in the field of personalized healthcare. The company is dedicated to discovering genes associated with complex diseases and commercializing molecular diagnostic tests to enable individualized diagnosis, prevention and treatment. IntegraGenís proprietary gene mapping technology GenomeHIPô provides fast, reliable, and cost-effective discovery of genetic loci. Paired with strong biostatistics, bioinformatics and fine mapping genotyping capabilities, IntegraGen has successfully identified and patented genes associated with early and late onset diseases. Founded in 2000, IntegraGen has 34 employees. IntegraGen is headquartered in Evry, near Paris. More information can be found at


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.